Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+prostate+cancer

44 Results

Sort By:

PSMA-targeted Nanoparticles for Therapy of Prostate Cancer

PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:· Engineered nanoparticle system with potent urea-based PSMA inhibitor· Drug loaded nanoparticle· Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...

Published: 1/22/2026 | Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Intranasal Delivery of Testosterone Prodrugs to the CNS

Unmet NeedProstate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable but is treatable. The gold standard of care is androgen...

Published: 1/22/2026 | Inventor(s): Rana Rais, Barbara Slusher, Mark Markowski, Arindom Pal

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Small Molecules

DNA methylation markers for metastatic prostate cancer

Value Proposition:· Detection of methylation patterns that are linked to prostate cancer development in an individual.· Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.· Simultaneous determination of gene methylation and copy number. Technology DescriptionResearchers at Johns Hopkins...

Published: 1/22/2026 | Inventor(s): George Bova, William Nelson, Martin Aryee, William Isaacs, Srinivasan Yegnasubramanian

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Epigenetic, In Vitro Diagnostics, Mechanism-of-action Biomarker, Methylation, Prostate Cancer, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Mechanism-based 3rd Generation Quinoline-3-carboxamide HDAC4 Inhibitor for Metastatic Castration-resistant Prostate Cancer

Value Proposition:· Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)· HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC· Similar anti-cancer agents must be dosed at lower concentrations...

Published: 1/22/2026 | Inventor(s): John Isaacs, William Brennen, Emmanuel Akinboye

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Oncology

Urinary Glycoproteins for the Early Detection of Aggressive Prostate Cancer

Unmet NeedAccording to the American Cancer Society, prostate cancer is one of the most commonly diagnosed cancers and is the second leading cause of cancer death in men. However, most patients with prostate cancer have the low-risk, nonaggressive form that does not require invasive intervention or treatment. The gold standard of diagnosing men with...

Published: 1/22/2026 | Inventor(s): Hui Zhang, Mingming Dong, Tung-Shing Lih

Keywords(s): Assay, Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics (Old), Prostate Cancer

Category(s): Technology Classifications > Diagnostics > Prognostic Biomarkers, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Diagnostics > In Vitro Diagnostics

Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs

Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...

Published: 1/22/2026 | Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Apparatus and Methods for Ultrasound Screening of Prostate Cancer

Unmet NeedProstate cancer is the second most common type of cancer in American men, behind skin cancer. It is also the second leading cause of cancer deaths in American males, and there is a continuing need for innovation in diagnosis for those at risk for prostate cancer. After initial diagnostic blood tests for prostate-specific antigens, a prostate...

Published: 1/22/2026 | Inventor(s): Emad Boctor, Bradford Wood, Reza Seifabadi, Fereshteh Aalamifar

Keywords(s): Clinical Diagnostics, Diagnostic Tool, Image Processing Software, Imaging Probe/Transducer, Interventional and Surgical Systems, Mapping Tool, Surgical Navigation

Category(s): Technology Classifications > Medical Devices > Imaging, Clinical and Disease Specializations > Oncology > Prostate Cancer

Androgen Receptor and AR-V7 Knock-out Lines from the LNCaP95 Cell Line

Unmet NeedProstate cancer is considered the most common type of cancer in men with approximately 249,000 new cases and an estimated 34,130 deaths in 2021 (see ACS). Prostate cancer treatment is dependent on tumor staging with early stage intervention including surgery or radiotherapy and later stage management by androgen deprivation therapy (see Uptodate)....

Published: 1/22/2026 | Inventor(s): Jun Luo, Yezi Zhu, Changxue Lu

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Research Tools > Cell Lines

Detection of Prostate Cancer Proteins in Serum for Cancer Diagnosis with a Blood Test

There is a crucial need of discovering novel biomarkers in addition to prostate specific antigen (PSA) to improve the specificity of clinical diagnosis for prostate cancer. This invention addresses this problem by discovering proteins from prostate cancer tissues that can be detected in patients’ blood. Hence, a blood test can be developed for detecting...

Published: 1/22/2026 | Inventor(s): Yan Li, Daniel Chan, Zhen Zhang, Lori Sokoll, Hui Zhang

Keywords(s): Assay, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Prostate Cancer

Sequential Hormone Therapy to Improve Survival and Enhance Response to Immune Therapy in Men with Prostate Cancer

Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an unmet clinical need to overcome resistance to hormone...

Published: 1/22/2026 | Inventor(s): Samuel Denmeade, John Isaacs, Emmanuel Antonarakis, Sushant Kachhap, Mark Markowski

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities

1 2 3 4 5